Kexing Biopharm Co., Ltd. (SHSE: 688136)
Health Care · Biotechnology · CN
CN¥23.24
-4.24% today · -40.8% 1Y
Kexing Biopharm Co., Ltd. (SHSE: 688136) operates in the Biotechnology industry within the Health Care sector. The company is valued at $689.04M and employs 1,109 people.
Over the last twelve months the share price has lost 40.8%, trading between 17.00 and 41.50.
Tweenvest scores Kexing Biopharm Co., Ltd. across four factors: quality 65/100, value 43/100, growth 60/100, dividend 7/100. Its strongest factor is quality.
688136 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $689.04M
- Revenue (TTM)
- $212.09M
- P/E
- 21.94
- EPS
- 1.06
- Dividend yield
- 1.08%
- Beta (5Y)
- 0.35
- 52-week high
- CN¥41.50
- 52-week low
- CN¥17.00
- Avg volume (3M)
- —
- Shares outstanding
- 198.59M
- Employees
- 1,109
- Next earnings
- —
About Kexing Biopharm Co., Ltd.
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
- ISIN
- CNE100006ZG6
- Founded
- 1997
- Listed since
- Dec 14, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ChemPartner PharmaTech Co.,Ltd.SZSE: 300149 | $713.97M | CN¥9.47 | -4.34% |
| Avalo Therapeutics, Inc.NasdaqCM: AVTX | $710.06M | $13.24 | -3.00% |
| MiMedx Group, Inc.NasdaqCM: MDXG | $704.02M | $4.83 | +3.43% |
| Pharming Group N.V.ENXTAM: PHARM | $691.81M | €0.88 | -0.16% |
| Nuvectis Pharma, Inc.NasdaqCM: NVCT | $688.12M | $19.69 | -6.77% |
| Olema Pharmaceuticals, Inc.NasdaqGS: OLMA | $684.23M | $7.36 | -5.88% |
| Design Therapeutics, Inc.NasdaqGS: DSGN | $682.77M | $10.91 | -6.35% |
| Aura Biosciences, Inc.NasdaqGM: AURA | $678.23M | $6.54 | 0.00% |
Figures last refreshed Oct 11, 2026.